Welcome to our dedicated page for BioRestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on BioRestorative Therapies stock.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) is a cutting-edge biotechnology company based in the United States, dedicated to developing regenerative medicine products and therapies using cell and tissue protocols, particularly involving adult stem cells. The company’s core focuses are its Disc/Spine Program and Metabolic Program.
In the Disc/Spine Program, their lead cell therapy candidate, BRTX-100, is formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow. This innovative treatment is designed for the non-surgical management of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. BRTX-100 undergoes a meticulous production process, starting from the collection of a patient’s bone marrow, followed by the isolation and culturing of stem cells, and finally cryopreserving these cells. The therapy involves injecting BRTX-100 into the patient's damaged disc, offering hope for patients whose pain has not been alleviated by other non-invasive treatments.
The Metabolic Program focuses on developing cell-based therapies to combat obesity and metabolic disorders using brown adipose-derived stem cells. This innovative approach aims to generate brown adipose tissue to help address these widespread health issues.
BioRestorative Therapies is also venturing into the rapidly growing bio-cosmeceutical market. The company recently signed a five-year exclusive supply agreement with Cartessa Aesthetics, LLC, a prominent North American aesthetics company. This partnership aims to introduce proprietary cell-based innovations to the aesthetics market, leveraging both BioRestorative’s expertise in cell-based biologics and Cartessa’s strong market presence.
Financially, BioRestorative is strong, ending 2023 with around $11.1 million in cash and cash equivalents, and an additional $7.6 million from a recent private placement. This solid financial standing, combined with expected revenues from its new commercial products, allows the company to pursue further advancements in their clinical and preclinical pipelines, including their BRTX-100 and ThermoStem® programs.
For more information, visit BioRestorative Therapies or contact Investor Relations at ir@biorestorative.com.
FAQ
What is the current stock price of BioRestorative Therapies (BRTX)?
What is the market cap of BioRestorative Therapies (BRTX)?
What does BioRestorative Therapies, Inc. specialize in?
What are the main programs developed by BioRestorative Therapies?
What is BRTX-100?
How does BRTX-100 work?
What recent partnership has BioRestorative Therapies entered into?
How financially stable is BioRestorative Therapies?
What are the potential benefits of the partnership with Cartessa Aesthetics?
What is the focus of BioRestorative's Metabolic Program?
Who can I contact for investor relations at BioRestorative Therapies?
Where can I find more information about BioRestorative Therapies?
